EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses

Peter Pushko iD, Igor S Lukashevich iD, Dylan M Johnson iD, Irina Tretyakova

Viruses · 10.03.2024 · 16 (3) · 428

DOI: 10.3390/v16030428 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 10.03.2024. Verfasst von Peter Pushko und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medigen, Inc., 8420 Gas House Pike Suite S, Frederick, MD 21701, USA. Hauptthemen laut MEDLINE: Vaccines, DNA, Flavivirus, Viral Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH NIAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Single-dose, immunogenic DNA (iDNA) vaccines coding for whole live-attenuated viruses are reviewed. This platform, sometimes called immunization DNA, has been used for vaccine development for flavi- and alphaviruses. An iDNA vaccine uses plasmid DNA to launch live-attenuated virus vaccines in vitro or in vivo. When iDNA is injected into mammalian cells in vitro or in vivo, the RNA genome of an attenuated virus is transcribed, which starts replication of a defined, live-attenuated vaccine virus in cell culture or the cells of a vaccine recipient. In the latter case, an immune response to the live virus vaccine is elicited, which protects against the pathogenic virus. Unlike other nucleic acid vaccines, such as mRNA and standard DNA vaccines, iDNA vaccines elicit protection with a single dose, thus providing major improvement to epidemic preparedness. Still, iDNA vaccines retain the advantages of other nucleic acid vaccines. In summary, the iDNA platform combines the advantages of reverse genetics and DNA immunization with the high immunogenicity of live-attenuated vaccines, resulting in enhanced safety and immunogenicity. This vaccine platform has expanded the field of genetic DNA and RNA vaccines with a novel type of immunogenic DNA vaccines that encode entire live-attenuated viruses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, DNAFlavivirusViral VaccinesAnimalsAntibodies, ViralVaccines, AttenuatedDNAMammals

Stichwörter der Autor:innen

DNA vaccinealphavirusattenuated virusflavivirusiDNAlive virus vaccine

Substanzen

Antibodies, ViralVaccines, DNAViral VaccinesVaccines, AttenuatedDNA

Autor:innen und Institutionen

  • Medigen, Inc., 8420 Gas House Pike Suite S, Frederick, MD 21701, USA.
  • Department of Pharmacology and Toxicology, School of Medicine, Center for Predictive Medicine and Emerging Infectious Diseases, University of Louisville, 505 S Hancock St., Louisville, KY 40202, USA.
  • Department of Biotechnology & Bioengineering, Sandia National Laboratories, Livermore, CA 945501, USA.

ORCID-Profile: Peter Pushko, Igor S Lukashevich, Dylan M Johnson

Förderung

  • NIAID NIH HHS
  • NIH NIAID

Zitieren

APA

Pushko, P., Lukashevich, I. S., Johnson, D. M., & Tretyakova, I. (2024). Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses. Viruses, 16(3), 428. https://doi.org/10.3390/v16030428

Vancouver

Pushko P, Lukashevich IS, Johnson DM, Tretyakova I. Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses. Viruses. 2024;16(3):428. doi:10.3390/v16030428

BibTeX
@article{Pushko2024,
  author = {Pushko, Peter and Lukashevich, Igor S and Johnson, Dylan M and Tretyakova, Irina},
  title = {Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses},
  journal = {Viruses},
  year = {2024},
  volume = {16},
  number = {3},
  pages = {428},
  doi = {10.3390/v16030428}
}
Kostenlos starten →